The ASCO Post

The ASCO Post
Surveillance Protocol and Early Cancer Detection in Patients With Constitutional Mismatch Repair Deficiency Syndrome

Use of an IRRDC surveillance protocol is associated with improved OS among patients with CMMRD, a cancer predisposition syndrome associated with inheritance of biallelic pathogenic variants in mism

The ASCO Post
Evolution to HER2-Low Breast Cancer: Investigating Potential Therapeutics

The finding that breast tumors can evolve to express low HER2 potentially increases the number of patients who can benefit from new investigational agents, typically novel antibody-drug conjugate t

The ASCO Post
Phase III ARIEL4 Confirms Rucaparib’s Benefit in BRCA-Mutated Relapsed Ovarian Cancer

In patients with BRCA-mutated, advanced, relapsed ovarian cancer, treatment with the PARP inhibitor rucaparib leads to a significant improvement in PFS compared with standard-of-care CT.

The ASCO Post
First-Line Pembrolizumab Plus Chemotherapy in PD-L1–Positive Locally Recurrent Triple-Negative Breast Cancer

The addition of pembrolizumab to CT improves PFS among previously untreated patients with locally recurrent inoperable or metastatic TNBC with a PD-L1 expression combined positive score ≥ 10.

The ASCO Post
Neoadjuvant Nivolumab Plus Chemotherapy Boosts Pathologic Complete Response in Resectable NSCLC

Neoadjuvant CT with nivolumab plus platinum-doublet chemotherapy significantly improves pathologic complete response rates compared with CT alone in patients with resectable stage IB to IIIA NSCLC.

The ASCO Post
Effect of Oral Chemotherapy Management Program on Capecitabine Toxicity

This study finds that implementation of an oral CT management program is associated with reduced rates of any-grade and severe capecitabine toxicity, less frequent toxicity-related...

The ASCO Post
Relationship Between Germline BRCA Pathogenic Variants and Diminished Ovarian Reserve

Turan et al find the presence of germline BRCA pathogenic variants is associated with diminished ovarian reserve in young women, particularly in those diagnosed with breast cancer and...

The ASCO Post
Expert Panel–Endorsed Quality Measures for End-of-Life Care for Children With Cancer

There is currently no consensus on what quality end-of-life care for children with cancer looks like, or how to measure and deliver it; however, investigators recently assembled an expert panel...<

The ASCO Post
FDA Grants Accelerated Approval to Pembrolizumab Combination for HER2-Positive Gastric Cancer

The FDA approves pembrolizumab in combination with trastuzumab plus fluoropyrimidine- and platinum-containing CT for the first-line treatment of patients with locally advanced unresectable or metas

The ASCO Post
Ten-Year Outcomes With Neoadjuvant Chemoradiotherapy Plus Surgery vs Surgery Alone for Esophageal Cancer

This 10-year follow-up of the Dutch CROSS trial shows a continued OS benefit with neoadjuvant chemoradiotherapy plus surgery vs surgery alone in patients with locally advanced resectable esophageal

The ASCO Post
Subscribe to The ASCO Post

source list reference